H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Signs Lease Agreement in Houston
- Plus Therapeutics provides update on CNSide Diagnostic platform launch
- PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test
- Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments